Mark J. Edlund

Mark J. Edlund

Auto-generated profile, based on publicly available information

Mark J. Edlund

RTI Int, Res Triangle Pk, NC USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
MEMark J. Edlund
Mark J. Edlund
BMBradley C. Martin
Bradley C. Martin
JRJoan E. Russo
Joan E. Russo
ADAndrea DeVries
Andrea DeVries
JBJennifer B. Braden
Jennifer B. Braden
MSMark D. Sullivan
Mark D. Sullivan
Objective: Increasing rates of opioid use disorders (OUDs) (abuse and dependence) among patients prescribed opioids are a significant public health concern. We investigated the association between exposure to prescription opioids and incident OUDs among individuals with a new episode of a chronic noncancer pain (CNCP) condition. Methods: We utilized claims data from the HealthCore Database for 2000 to 2005. The dataset included all individuals aged 18 and over with a new CNCP episode (no diagnosis in the prior 6 mo), and no opioid use or OUD in the prior 6 months (n=568,640). We constructed a single multinomial variable describing prescription on opioid days supply (none, acute, and chronic) and average daily dose (none, low dose, medium dose, and high dose), and examined the association between this variable and an incident OUD diagnosis. Results: Patients with CNCP prescribed opioids had significantly higher rates of OUDs compared with those not prescribed opioids. Effects varied by average daily dose and days supply: low dose, acute (odds ratio [OR]=3.03; 95% confidence interval [CI], 2.32, 3.95); low dose, chronic (OR=14.92; 95% CI, 10.38, 21.46); medium dose, acute (OR=2.80; 95% CI, 2.12, 3.71); medium dose, chronic (OR=28.69; 95% CI, 20.02, 41.13); high dose, acute (OR=3.10; 95% CI, 1.67, 5.77); and high dose, chronic (OR=122.45; 95% CI, 72.79, 205.99). Conclusions: Among individuals with a new CNCP episode, prescription opioid exposure was a strong risk factor for incident OUDs; magnitudes of effects were large. Duration of opioid therapy was more important than daily dose in determining OUD risk.

1 July 2015 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
MEMark J. Edlund
Mark J. Edlund
VFValerie L. Forman-Hoffman
Valerie L. Forman-Hoffman
CWCherie R. Winder
Cherie R. Winder
DHDavid C. Heller
David C. Heller
LKLarry A. Kroutil
Larry A. Kroutil
LCLisa J. Colpe
Lisa J. Colpe

1 July 2012 in Journal of Studies on Alcohol and Drugs
Verified
Journal Article
Closed access
MEMark J. Edlund
Mark J. Edlund
BBBrenda M. Booth
Brenda M. Booth
XHXiaotong Han
Xiaotong Han
Objective:Only a fraction of individuals with alcohol use disorders (AUDs) receive any AUD treatment during a given year. If a substantial proportion of individuals with unmet need for AUD treatmen...

1 November 2014 in Pain
Verified
Journal Article
Closed access
MEMark J. Edlund
Mark J. Edlund
MAMark A. Austen
Mark A. Austen
MSMark D. Sullivan
Mark D. Sullivan
BMBradley C. Martin
Bradley C. Martin
JWJames S Williams
James S Williams
THTeresa J. Hudson
Teresa J. Hudson
Although opioids are frequently prescribed for chronic noncancer pain (CNCP) among Veterans Health Administration (VHA) patients, little has been reported on national opioid prescribing patterns in the VHA. Our objective was to better characterize the dosing and duration of opioid therapy for CNCP in the VHA. We analyzed national VHA administrative and pharmacy data for fiscal years 2009 to 2011. For individuals with CNCP diagnoses and any opioid use in the fiscal year, we calculated the distribution of individual mean daily opioid dose, individual total days covered with opioids in a year, and individual total opioid dose in a year. We also investigated the factors associated with being in the top 5% of individuals for total opioid dose in a year, which we term receipt of high-volume opioids. About half of the patients with CNCP received opioids in a given fiscal year. The median daily dose was 21 mg morphine equivalents. Approximately 4.5% had a mean daily dose higher than 120 mg morphine equivalents. The median days covered in a year was 115 to 120 days in these years for those receiving opioids. Fifty-seven percent had at least 90 days covered with opioids per year. Major depression and posttraumatic stress disorder were positively associated with receiving high-volume opioids, but nonopioid substance use disorders were not. Among VHA patients with CNCP, chronic opioid therapy occurs frequently, but for most patients, the average daily dose is modest. Doses and duration of therapy were unchanged from 2009 to 2011.

29 June 2018 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
MEMark J. Edlund
Mark J. Edlund
JWJiantong Wang
Jiantong Wang
KBKristen Gulledge Brown
Kristen Gulledge Brown
VFValerie L. Forman-Hoffman
Valerie L. Forman-Hoffman
SCSara L. Calvin
Sara L. Calvin
JBJonaki Bose
Jonaki Bose

1 August 2013 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
MEMark J. Edlund
Mark J. Edlund
MSMark D. Sullivan
Mark D. Sullivan
XHXiaotong Han
Xiaotong Han
BBBrenda M. Booth
Brenda M. Booth
Objectives: We investigated possible associations between pain frequency and the 5 most common substance use disorders: alcohol abuse/dependence, cocaine abuse/dependence, methamphetamine abuse/dependence, opioid abuse/dependence, and marijuana abuse/dependence. Methods: We used data from the Rural Stimulant Study, a longitudinal (7 waves), observational study of at-risk stimulant users (cocaine and methamphetamine) in Arkansas and Kentucky (n=462). In fixed-effects logistic regression models, we regressed our measures of substance use disorders on the number of days with pain in the past 30 days and depression severity. Results: Time periods when individuals had 1 to 15 days [odds ratio (OR)=1.85, P<0.001] or 16+ days (OR=2.18, P<0.001) with pain in the past 30 days were more likely to have a diagnosis of alcohol abuse/dependence, compared with time periods when individuals had no days with pain. Compared with time periods when individuals had no pain days in the past 30 days, time periods when individuals had 16+ pain days were more likely to have a diagnosis of opioid abuse/dependence (OR=3.32, P=0.02). Number of days with pain was not significantly associated with other substance use disorders. Discussion: Pain frequency seems to be associated with an increased risk for alcohol abuse/dependence and opioid abuse/dependence in this population, and the magnitude of the association is medium to large. Further research is needed to investigate this in more representative populations and to determine causal relationships.